StockStory picks Cigna and Astrana Health as long-term buys, flags Phibro Animal Health as a sell

Industry
โดย StockStory·Read original
Summary · why it matters

StockStory recommends Cigna and Astrana Health for long-term investors while advising against Phibro Animal Health. Cigna is highlighted for its 16.1% annual revenue growth over two years, $277.7 billion in revenue, and 10.9% annual EPS growth over five years. Astrana Health is noted for 55.7% annual revenue growth over two years and 13.2% annual EPS growth over five years. Phibro Animal Health is flagged for its modest $1.5 billion revenue base, projected 2.2% sales growth, and a weak 0.8% free cash flow margin over five years.

Impact on stocks 4

Health Care± Mixed · 2 stocks
Cigna Corp
CI
▲ PositiveCapitalrelevance

StockStory recommends Cigna as a long-term buy, highlighting its revenue and EPS growth.

Aging Population▲ · 1 stocks
Astrana Health Inc
ASTH
▲ PositiveCapitalrelevance

StockStory recommends Astrana Health as a long-term buy, citing strong revenue and EPS growth.

Consumer Staples▲ · 1 stocks
© 2026 MarketDXNews